An iterative computational design approach to increase the thermal endurance of a mesophilic enzyme.
Biotechnology For Biofuels
Sammond, Deanne W DW; Kastelowitz, Noah N; Donohoe, Bryon S BS; Alahuhta, Markus M; Lunin, Vladimir V VV; Chung, Daehwan D; Sarai, Nicholas S NS; Yin, Hang H; Mittal, Ashutosh A; Himmel, Michael E ME; Guss, Adam M AM; Bomble, Yannick J YJ
Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals.
Journal Of The International Aids Society
Arruda, Monica B MB; Boullosa, Lídia T LT; Cardoso, Cynthia C CC; da Costa, Carolina M CM; Alves, Carlos Rb CR; de Lima, Shirlene Ts ST; Kaminski, Helena T HT; Aleixo, Agdemir W AW; Esposito, Ana Op AO; Cavalcanti, Ana Ms AM; Riedel, Maristela M; Couto-Fernandez, José C JC; Ferreira, Selma B SB; de Oliveira, Ivi Cm IC; Portal, Loreci E LE; Wolf, Hilda Hc HH; Fernandes, Sandra B SB; de M C Pardini, Maria I MI; Feiteiro, Manoel Vc MV; Tolentino, Fernanda M FM; Diaz, Ricardo S RS; Lopes, Giselle Isl GI; Francisco, Roberta Bl RB; Véras, Nazle Mc NM; Pires, Ana F AF; Franchini, Miriam M; Mesquita, Fábio F; Tanuri, Amilcar A; ,
Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients.
Aids Research And Therapy
Mata-Marín, José Antonio JA; Huerta-García, Gloria G; Domínguez-Hermosillo, Juan Carlos JC; Chavez-García, Marcelino M; Banda-Lara, Marco Isaac MI; Nuñez-Rodríguez, Nohemí N; Cruz-Herrera, Javier Enrique JE; Sandoval-Ramírez, Jorge Luis JL; Martínez-Abarca, Ivan I; Villagómez-Ruíz, Alfredo Francisco AF; Manjarrez-Tellez, Bulmaro B; Gaytán-Martínez, Jesús J
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Plos One
Sutherland, Katherine A KA; Parry, Chris M CM; McCormick, Adele A; Kapaata, Anne A; Lyagoba, Fred F; Kaleebu, Pontiano P; Gilks, Charles F CF; Goodall, Ruth R; Spyer, Moira M; Kityo, Cissy C; Pillay, Deenan D; Gupta, Ravindra K RK; ,
Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
Plos One
Smith, Robert A RA; Raugi, Dana N DN; Pan, Charlotte C; Coyne, Matthew M; Hernandez, Alexandra A; Church, Brad B; Parker, Kara K; Mullins, James I JI; Sow, Papa Salif PS; Gottlieb, Geoffrey S GS; ,